Gevorg Tamamyan: Happy Birthday OncoDaily
FDA Grants Approval for Oral Decitabine/Cedazuridine with Venetoclax in Newly Diagnosed AML
How I Treat Bladder Cancer in 2026: OncoDaily Virtual Summit
Herbert Loong Invites to Attend the Sarcoma Grand Rounds at ASCO 2026
OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition
Episode 15: Global Health Dialogues with Princess Dina and Dr Garo Armen
ASCO 2026 with OncoDaily: Yvonne Awards, AI in Oncology, Grand Rounds and Live Coverage from Chicago
Grand Rounds by OncoDaily: AI in Oncology Edition
Enter RS and clinical context to view RS category and trial-aligned interpretation for early HR+/HER2- breast cancer.
This calculator is intended for ER/PR+ HER2- breast cancer only
TAILORx (Node-negative): Demonstrated that chemotherapy provides minimal to no benefit for most patients with RS 11-25. For patients ≤50 years, some benefit may be seen in RS 16-25.
RxPONDER (Node-positive, 1-3 nodes): Showed that postmenopausal patients with RS 0-25 did not benefit from chemotherapy. Premenopausal patients derived benefit regardless of RS.
RS Categories:
Low
0-10
Intermediate
11-25
High
26-100
